Currently out of the existing stock ratings of David Nierengarten, 263 are a BUY (81.68%), 58 are a HOLD (18.01%), 1 are a SELL (0.31%).

David Nierengarten

Work Performance Price Targets & Ratings Chart

Analyst David Nierengarten, currently employed at WEDBUSH, carries an average stock price target met ratio of 44.23% that have a potential upside of 45.68% achieved within 213 days.

David Nierengarten’s has documented 730 price targets and ratings displayed on 59 stocks. The coverage is on Healthcare, Communication Services, Technology sectors.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 18-Nov-2024.

Wall Street Analyst David Nierengarten

Analyst best performing recommendations are on SRRK (SCHOLAR ROCK HOLDING CORP).
The best stock recommendation documented was for SRRK (SCHOLAR ROCK HOLDING CORP) at 6/18/2018. The price target of $25 was fulfilled within 1 day with a profit of $3.57 (16.66%) receiving and performance score of 166.59.

Average potential price target upside

of $156.05 (47.33%) on NFLX (NETFLIX).
of $56.48 (24.89%) on ARGX (ARGENX NV ADR).
of $26.58 (57.3%) on MYOK (MYOKARDIA).

ANAB AnaptysBio ARAV Aravive ARGX argenx NV ADR AVRO AVROBIO BEAM Beam Therapeutics BLUE Bluebird bio BPMC Blueprint Medicines Corp CDAK Codiak BioSciences COGT Cogent Biosciences EPZM Epizyme FATE Fate Therapeutics GTHX G1 Therapeutics INZY Inozyme Pharma ITOS Iteos Therapeutics KPTI Karyopharm Therapeutics MGNX MacroGenics MYOK MyoKardia NTLA Intellia Therapeutics NUVB Nuvation Bio NVCR Novocure Ltd ORTX Orchard Therapeutics PLC STML Stemline Therapeutics STRO Sutro Biopharma TC TuanChe ADR TCRR Tcr2 Therapeutics TPTX Turning Point Therapeutics TSVT 2Seventy Bio XNCR Xencor YMAB Y mAbs Therapeutics CDTX Cidara Therapeutics KNSA Kiniksa Pharmaceuticals Ltd SRRK Scholar Rock Holding Corp SWTX SpringWorks Therapeutics VYGR Voyager Therapeutics AGTC Applied Genetic ARDX Ardelyx MRUS Merus BV PRTA Prothena plc RARE Ultragenyx KNTE Kinnate Biopharma VOR Vor Biopharma BMRN Biomarin Pharmaceutical MGTA Magenta Therapeutics NFLX Netflix BOLD Audentes Therapeutics FENC Fennec Pharmaceuticals ISEE IVERIC bio NUVL Nuvalent ONCE Spark Therapeutics THRX Theseus Pharmaceuticals CMRX Chimerix MRSN Mersana Therapeutics FRLN Freeline Therapeutics Holdings Plc GBIO Generation Bio Co FUSN Fusion Pharmaceuticals MAXN Maxeon Solar Technologies Ltd ORIC Oric Pharmaceuticals IMNM Immunome TCRX Tscan Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Anupam Rama (JPMORGAN)